Related Experiment Video

Updated: Jul 11, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

352

New insights into the interaction between m6A modification and lncRNA in cancer drug resistance

Yizhou Jin1, Zhipeng Fan1,2,3

  • 1Beijing Key Laboratory of Tooth Regeneration and Function Reconstruction, Beijing Stomatological Hospital, School of Stomatology, Capital Medical University, Beijing, China.

Cell Proliferation
|November 14, 2023
PubMed

Insights

Drug resistance in cancer is a major challenge. This review explores how N6-methyladenosine (m6A) RNA modifications and long noncoding RNAs (lncRNAs) interact to influence cancer drug resistance and metastasis.

Area of Science:

  • Molecular Biology
  • Oncology
  • RNA Biology

Background:

  • Drug resistance is a primary obstacle in cancer treatment, leading to recurrence and metastasis.
  • N6-methyladenosine (m6A) is a key RNA modification regulating gene expression.
  • Long noncoding RNAs (lncRNAs) are crucial in tumor development and treatment resistance.

Purpose of the Study:

  • To review recent advancements in the interplay between m6A modification and lncRNA in cancer drug resistance.
  • To explore the underlying molecular mechanisms of this interaction.
  • To suggest future directions for overcoming chemoresistance.

Main Methods:

  • Literature review of recent studies on m6A modification and lncRNA in cancer.
  • Analysis of mechanisms modulating cancer drug sensitivity.
  • Synthesis of current knowledge on m6A-lncRNA interactions.

Main Results:

  • Evidence highlights the critical role of m6A modification and lncRNA interplay in cancer cell sensitivity to chemotherapy.
  • This interaction influences multiple cancer hallmarks, including proliferation, metastasis, and metabolism.
  • Specific m6A-lncRNA interactions are increasingly identified as key regulators of drug resistance.

Conclusions:

  • The interplay between m6A modification and lncRNA is a significant factor in cancer drug resistance.
  • Understanding these mechanisms offers potential therapeutic targets for reversing chemoresistance.
  • Further research into m6A-lncRNA interactions could lead to novel strategies for improving cancer patient outcomes.

More Related Videos

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.8K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K